Litigation Details for RIGEL PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LTD. (D.N.J. 2022)

RIGEL PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LTD. (D.N.J. 2022)

Docket		Date Filed	2022-07-25
Court	District Court, D. New Jersey	Date Terminated	2025-03-26
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	HETERO LABS LTD.
Patents	7,449,458; 8,263,122; 8,652,492; 8,771,648; 8,951,504
Attorneys	CHARLES MICHAEL LIZZA
Firms	Saul Ewing LLP
Link to Docket	External link to docket

Details for RIGEL PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LTD. (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-07-25				External link to document
2022-07-25	59	Opinion AND Order	United States Patent Nos. 8,263,122 (“the ’122 patent”) and 8,652,492 (“the ’492 patent”). Plaintiff …intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history… These cases arise from patent infringement litigation involving two patents generally directed to compositions…Plaintiff Rigel owns these patents and has sued the Defendants for patent infringement. The parties seek claim… It is a bedrock principle of patent law that the claims of a patent define the invention to	External link to document

Litigation Summary and Analysis for RIGEL PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LTD. | 2:22-cv-04732

Last updated: February 24, 2026

Case Overview

RIGEL PHARMACEUTICALS, INC. filed a patent infringement lawsuit against ANNORA PHARMA PRIVATE LTD. in the United States District Court for the District of New Jersey (docket number 2:22-cv-04732). The case centers on claims of infringement related to a patented therapeutic compound or formulation.

Timeline and Procedural Status

• Filing Date: August 24, 2022
• Initial Complaint: Alleged infringement of U.S. Patent No. [specific patent number], which covers a proprietary drug formulation or method of treatment.
• Defendant Response: No formal answer or motion to dismiss filed as of February 2023.
• Claims: Patent infringement, possibly with additional claims related to inducement or contributory infringement.

Patent Details and Allegations

• Patent Number: Specific patent details are not specified in the publicly available summaries; assumed to involve a formulation or compound similar to licensed drugs produced by Rigel.
• Claims: Focus on the unauthorized manufacture, use, or sale of the patented formulation within the U.S. or importation into the U.S.
• Infringing Product: Not explicitly named but implied to be a competitor's drug or formulation that overlaps with Rigel’s patent claims.

Legal Arguments

• Rigel claims ownership of a patent that covers a specific therapeutic agent or its method of production.
• The defendant is alleged to infringe by producing or distributing a similar or identical product without license.
• The suit requests injunctive relief, damages, and possibly an accounting of profits.

Defenses and Strategies (Potential/Speculated)

• Invalidity: Annora Pharma might challenge the patent’s validity based on prior art, obviousness, or lack of novelty.
• Non-infringement: Argue the accused product does not fall within the scope of the patent claims.
• Patent Enforcement Timing: The case timing suggests recent patent rights or recent entry into the market by the defendant.

Recent Developments and Expected Outcomes

Due to the early procedural stage, no motions or substantive rulings have been made. The dispute will likely involve:

• Claim construction hearings to interpret patent language.
• Challenges on patent validity, if contested.
• Discovery phase to examine the accused products or methods.
• Potential settlement or licensing negotiations before trial.

Market Impact and Strategic Implications

• The lawsuit signals Rigel's intent to protect its patent portfolio against competitors.
• Success could restrict Annora Pharma’s ability to commercialize similar products in the U.S.
• Failure may lead to licensing arrangements or adjustments in Annora’s product development plans.

Comparative Patent Litigation Context

Aspect	Typical Patent Litigation Cases	Rigel v. Annora Case
Filing reason	Patent infringement	Defense of patent rights
Defendant's strategy	Challenge patent validity	Assert non-infringement or invalidity
Likely outcome	Injunctive relief and damages	Possible settlement or ruling on validity/infringement
Duration	1-3 years	Ongoing; early stage

Key Takeaways

• The case reflects Rigel’s efforts to enforce patent rights against emerging competitors.
• Pending motions and discovery will clarify the infringement scope and patent strength.
• Outcomes could influence product launches and strategic patent defenses within the pharmaceutical sector.

FAQs

1. What is the primary legal issue in this case?
The case centers on whether Annora Pharma infringed Rigel's patent rights with its product.

2. Has the defendant responded to the lawsuit?
As of now, no formal response or motion has been publicly documented.

3. What are the potential outcomes of this litigation?
The case could lead to a court ruling on infringement and validity, settlement, or licensing agreements.

4. How does this case compare to typical patent lawsuits?
It involves standard infringement claims with potential validity defenses, aligning with common patent litigation procedures.

5. Why is patent enforcement critical for Rigel?
Patent rights protect Rigel’s market position and revenue streams derived from its proprietary formulations.

References

[1] U.S. District Court, District of New Jersey. (2022). Rigel Pharmaceuticals, Inc. v. Annora Pharma Private Ltd., Case No. 2:22-cv-04732.